Takaoka, Japan

Ikumi Shimokawa

This inventor holds 1 USPTO granted patent. Top assignee: Kyowa Pharma Chemical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ikumi Shimokawa. Retrieved from https://idiyas.com/inventor/ikumi-shimokawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ikumi Shimokawa: Inventor in Chemical Production

Introduction

Ikumi Shimokawa is an inventor associated with Takaoka, Japan, and Kyowa Pharma Chemical Co., Ltd. Her patent work concerns methods for producing sulfur- and selenium-containing compounds.

Latest Patents

The supplied information lists one patent for Shimokawa: “Method for Producing Trisulfide Compound or Selenotrisulfide Compound.” The disclosed method first oxidizes a disulfide compound to obtain a sulfoxide compound. It then reacts the sulfoxide with a sulfur or selenium source to produce a trisulfide or selenotrisulfide compound. Shimokawa is credited with 1 patent.

Career Highlights

Shimokawa’s listed invention focuses on a chemical production process that uses sequential oxidation and reaction steps. The supplied information associates her work with Kyowa Pharma Chemical Co., Ltd.

Collaborations

Shoichiro Tomonaga is identified as Shimokawa’s coworker. The supplied information does not specify their roles in the patent or describe any particular collaboration.

Conclusion

Ikumi Shimokawa’s listed patent documents a method for producing trisulfide and selenotrisulfide compounds, reflecting her contribution to chemical-process innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…